A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
for Monoclonal Gammopathy of Undetermined Significance (MGUS)
Drug: Linvoseltamab
7 locations incl. Baltimore
Sponsor: Regeneron Pharmaceuticals
Sex: All·Age: 18+
Code: NCT06140524·Phase 2·Recruiting